ARTBIO, a clinical-stage radiopharmaceutical company, is focused on developing alpha radioligand therapies (ARTs) for various types of cancer. The company has secured $132 million in Series B financing, co-led by new investors Sofinnova Investments and B Capital, with support from other investors, including F-Prime, Omega Funds, and Qatar Investment Authority.
These funds will advance ARTBIO’s pipeline, particularly its lead program, AB001, for metastatic castration-resistant prostate cancer, into Phase II clinical trials. The company also aims to expand its manufacturing network to support global clinical trials and future commercialization.
A critical element of ARTBIO’s success is its patented AlphaDirect isotope isolation technology, which allows for daily production of clinical-grade lead-212 (212Pb) and therapeutic doses. This technology enhances accessibility and reduces supply chain risks through a strategically distributed manufacturing network.
KEY QUOTES:
“This sizable investment from both existing and new investors will enable ARTBIO to continue innovating therapies that treat a range of deadly cancers with power and precision. Our team is grateful for the investment and recognition of the need to build a supply chain that matches the properties of the therapies and the unique payload that we use.”
Emanuele Ostuni, Ph.D., CEO of ARTBIO
“ARTBIO’s approach to ART has the potential to positively change standards of care in cancer. ARTBIO’s lead asset, AB001, is designed to fully harness the unique power of lead-212. My team and I are excited for what’s to come.”
Robert Mittendorff, M.D., General Partner at B Capital
“With a differentiated ART portfolio and integrated manufacturing approach, ARTBIO represents the ideal company that we look to partner with. Equally impressive is their proprietary generator technology which is a game-changer for navigating around supply and production challenges for radioisotopes in today’s complex environment.”
Maha Katabi, Ph.D., General Partner at Sofinnova Investments
